Liliana Pires

Dr. Liliana Pires

RUBYnanomed
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Acta Biomaterialia
Verified
Journal Article
Closed access
CMC. Moreira
C. Moreira
HOH. Oliveira
H. Oliveira
Liliana PiresLiliana Pires
Liliana Pires
SSS. Simões
S. Simões
MBM.A. Barbosa
M.A. Barbosa
APAna Paula Pêgo
Ana Paula Pêgo

1 December 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ARAna Ramalheiro
Ana Ramalheiro
Juan L ParisJuan L Paris
Juan L Paris
Bruno SilvaBruno Silva
Bruno Silva
Liliana PiresLiliana Pires
Liliana Pires

15 November 2019 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Liliana PiresLiliana Pires
Liliana Pires
Vinaya kumar Kadayra BasavarajappaVinaya kumar Kadayra Basavarajappa
Vinaya kumar Kadayra Basavarajappa
MTMaria Turos
Maria Turos
VMVeronica Miguel
Veronica Miguel
JGJoão Gaspar
João Gaspar
Microneedles (MNs) have been extensively explored in the literature as a means to deliver drugs in the skin, surpassing the stratum corneum permeability barrier. MNs are potentially easy to produce and may allow the self-administration of drugs without causing pain or bleeding. More recently, MNs have been investigated to collect/assess the interstitial fluid in order to monitor or detect specific biomarkers. The integration of these two concepts in closed-loop devices holds the promise of automated and minimally invasive disease detection/monitoring and therapy. These assure low invasiveness and, importantly, open a window of opportunity for the application of population-specific and personalised therapies.

16 August 2013 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Open access
PDF file
Liliana PiresLiliana Pires
Liliana Pires
Vincenzo GuarinoVincenzo Guarino
Vincenzo Guarino
Maria  OliveiraMaria Oliveira
Maria Oliveira
CRCristina C. Ribeiro
Cristina C. Ribeiro
MBMário A Barbosa
Mário A Barbosa
APAna Paula Pêgo
Ana Paula Pêgo
The development of scaffolds that combine the delivery of drugs with the physical support provided by electrospun fibres holds great potential in the field of nerve regeneration. Here it is proposed the incorporation of ibuprofen, a well-known non-steroidal anti-inflammatory drug, in electrospun fibres of the statistical copolymer poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] to serve as a drug delivery system to enhance axonal regeneration in the context of a spinal cord lesion, by limiting the inflammatory response. P(TMC-CL) fibres were electrospun from mixtures of dichloromethane (DCM) and dimethylformamide (DMF). The solvent mixture applied influenced fibre morphology, as well as mean fibre diameter, which decreased as the DMF content in solution increased. Ibuprofen-loaded fibres were prepared from P(TMC-CL) solutions containing 5% ibuprofen (w/w of polymer). Increasing drug content to 10% led to jet instability, resulting in the formation of a less homogeneous fibrous mesh. Under the optimized conditions, drug-loading efficiency was above 80%. Confocal Raman mapping showed no preferential distribution of ibuprofen in P(TMC-CL) fibres. Under physiological conditions ibuprofen was released in 24 h. The release process being diffusion-dependent for fibres prepared from DCM solutions, in contrast to fibres prepared from DCM–DMF mixtures where burst release occurred. The biological activity of the drug released was demonstrated using human-derived macrophages. The release of prostaglandin E2 to the cell culture medium was reduced when cells were incubated with ibuprofen-loaded P(TMC-CL) fibres, confirming the biological significance of the drug delivery strategy presented. Overall, this study constitutes an important contribution to the design of a P(TMC-CL)-based nerve conduit with anti-inflammatory properties. Copyright © 2013 John Wiley & Sons, Ltd.

3 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CLCláudia Lopes
Cláudia Lopes
PPPaulina Piairo
Paulina Piairo
ACAlexandre Chicharo
Alexandre Chicharo
SASara Abalde-Cela
Sara Abalde-Cela
Liliana PiresLiliana Pires
Liliana Pires
LDLorena Dieguez
Lorena Dieguez
HER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot of the tumour burden. Liquid biopsy offers the unique opportunity for low invasive sampling in cancer patients and holds the potential to provide valuable information for the clinical management of cancer patients. This study assesses the performance of the RUBYchip™, a microfluidic system for CTC capture based on cell size and deformability, and compares it with the only FDA-approved technology for CTC enumeration, CellSearch®. After optimising device performance, 30 whole blood samples from metastatic breast cancer patients were processed with both technologies. The expression of HER2 was assessed in isolated CTCs and compared to tissue biopsy. Results show that the RUBYchipTM was able to isolate CTCs with higher efficiency than CellSearch®, up to 10 times more, averaging all samples. An accurate evaluation of different CTC subpopulations, including HER2+ CTCs, was provided. Liquid biopsy through the use of the RUBYchipTM in the clinic can overcome the limitations of histological testing and evaluate HER2 status in patients in real-time, helping to tailor treatment during disease evolution.

10 May 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
HOHugo Oliveira
Hugo Oliveira
RFRamon Fernandez
Ramon Fernandez
Liliana PiresLiliana Pires
Liliana Pires
MMMaria Cristina Martins
Maria Cristina Martins
SSSérgio Simões
Sérgio Simões
APAna Paula Pêgo
Ana Paula Pêgo